CN102159535A - 钾离子通道调节剂及其用途 - Google Patents

钾离子通道调节剂及其用途 Download PDF

Info

Publication number
CN102159535A
CN102159535A CN2009801378414A CN200980137841A CN102159535A CN 102159535 A CN102159535 A CN 102159535A CN 2009801378414 A CN2009801378414 A CN 2009801378414A CN 200980137841 A CN200980137841 A CN 200980137841A CN 102159535 A CN102159535 A CN 102159535A
Authority
CN
China
Prior art keywords
alkyl
carbon atom
group
compound
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801378414A
Other languages
English (en)
Chinese (zh)
Inventor
S·D·爱德华兹
M·R·金伯利
R·E·阿尔默
N·M·卡恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Original Assignee
Ramot at Tel Aviv University Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd filed Critical Ramot at Tel Aviv University Ltd
Publication of CN102159535A publication Critical patent/CN102159535A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN2009801378414A 2008-07-22 2009-07-20 钾离子通道调节剂及其用途 Pending CN102159535A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0813403.3A GB0813403D0 (en) 2008-07-22 2008-07-22 Potassium ion channel modulators & uses thereof
GB0813403.3 2008-07-22
PCT/GB2009/050887 WO2010010380A1 (en) 2008-07-22 2009-07-20 Potassium ion channel modulators & uses thereof

Publications (1)

Publication Number Publication Date
CN102159535A true CN102159535A (zh) 2011-08-17

Family

ID=39737453

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801378414A Pending CN102159535A (zh) 2008-07-22 2009-07-20 钾离子通道调节剂及其用途

Country Status (7)

Country Link
US (2) US9464052B2 (enExample)
EP (1) EP2310357B1 (enExample)
JP (1) JP2011529037A (enExample)
CN (1) CN102159535A (enExample)
DK (1) DK2310357T3 (enExample)
GB (1) GB0813403D0 (enExample)
WO (1) WO2010010380A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110913689A (zh) * 2017-05-10 2020-03-24 罗切斯特大学 治疗神经精神病症的方法
CN111433185A (zh) * 2017-10-09 2020-07-17 拉莫特特拉维夫大学有限公司 钾离子及trpv1通道的调节剂及其用途
CN117295711A (zh) * 2021-03-19 2023-12-26 艾可斯外扎根股份有限公司 Kv7通道开放剂的前药
US12084458B2 (en) 2021-02-19 2024-09-10 Sudo Biosciences Limited Substituted pyridines, pyridazines, and pyrimidines as TYK2 inhibitors
US12122785B2 (en) 2021-02-19 2024-10-22 Sudo Biosciences Limited Substituted pyridines, pyridazines, pyrimidines, and 1,2,4-triazines as TYK2 inhibitors

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0813403D0 (en) 2008-07-22 2008-08-27 Lectus Therapeutics Ltd Potassium ion channel modulators & uses thereof
US8624063B2 (en) 2009-06-30 2014-01-07 Wisconsin Alumni Research Foundation Non-lactone carbocyclic and heterocyclic antagonists and agonists of bacterial quorum sensing
WO2012007836A1 (en) 2010-07-16 2012-01-19 Purdue Pharma .Lp. Pyridine compounds as sodium channel blockers
MX2013003101A (es) 2010-09-17 2013-09-26 Purdue Pharma Lp Compuestos de piridina y sus usos.
US9376376B2 (en) * 2012-03-14 2016-06-28 Sinochem Corporation Substitute diphenylamine compounds use thereof as antitumor agents
AU2013203824A1 (en) 2012-03-16 2013-10-03 Purdue Pharma L.P. Substituted pyridines and pryimidines as sodium channel blockers
US9714252B2 (en) 2012-12-20 2017-07-25 Purdue Pharma L.P. Cyclic sulfonamides as sodium channel blockers
WO2017156519A1 (en) * 2016-03-11 2017-09-14 The Board Of Trustees Of The University Of Illinois Small-molecules active against gram-negative bacteria
US10526278B2 (en) 2017-10-19 2020-01-07 Wisconsin Alumni Research Foundation Inhibitors of quorum sensing receptor LasR
US20220324809A1 (en) * 2019-09-03 2022-10-13 Salzman Group Ltd. Atp-regulated potassium channel openers and uses thereof
JP7607864B2 (ja) * 2019-09-17 2025-01-06 バイオヘイブン・セラピューティクス・リミテッド Ｋｖ７チャネル活性化剤の使用方法
WO2022157686A1 (en) * 2021-01-22 2022-07-28 Ildong Pharmaceutical Co., Ltd. Inhibitors of anoctamin 6 protein and uses thereof
US12036286B2 (en) 2021-03-18 2024-07-16 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
US20250051319A1 (en) 2021-12-22 2025-02-13 Augustine Therapeutics Compounds and use thereof as hdac6 inhibitors
WO2023139581A1 (en) * 2022-01-18 2023-07-27 Bsense Bio Therapeutics Ltd. Modulators of a potassium channel and of trpv1 channel and uses thereof
CN120435316A (zh) * 2022-08-30 2025-08-05 拜奥海芬治疗学有限公司 包括金属通道激活剂和nmda受体拮抗剂的组合疗法
IT202200024948A1 (it) * 2022-12-05 2024-06-05 Angelini Pharma S P A Composti attivatori dei canali potassio KV7.2/KV7.3

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03278050A (ja) * 1990-03-27 1991-12-09 Konica Corp ハロゲン化銀写真感光材料
WO2001068619A1 (en) * 2000-03-15 2001-09-20 Warner-Lambert Company 5-amide substituted diarylamines as mex inhibitors
WO2004035037A2 (en) * 2002-10-21 2004-04-29 Ramot At Tel Aviv University Ltd. Derivatives of n-phenylanthranilic acid and 2-benzimidazolon as potassium channel and/or cortical neuron activity modulators
CN101184726A (zh) * 2004-12-15 2008-05-21 冬姆佩制药股份公司 2-芳基丙酸衍生物及包含它们的药物组合物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1882286A (en) * 1929-07-17 1932-10-11 Gen Aniline Works Inc Arylamides of meta-hydroxy-diarylamine-carboxylic acids and process of making same
BE590607A (enExample) 1960-02-24
US3413313A (en) * 1964-06-18 1968-11-26 Parke Davis & Co Anthranilic acid compounds and methods for their production
US4181519A (en) * 1977-01-21 1980-01-01 Shell Oil Company Diphenylamine derivative herbicides
CA1087186A (en) * 1977-01-21 1980-10-07 Kurt H. G. Pilgram Cycloalkane-carboxanilides
ZA865090B (en) * 1985-07-22 1988-02-24 Riker Laboratories Inc Substituted di-t-butylphenols
IL86462A (en) * 1987-05-29 1992-12-01 Fujisawa Pharmaceutical Co Alkanesulfonanilide derivatives, processes for preparation thereof and pharmaceutical compositions comprising the same
JPH0473190A (ja) * 1990-07-16 1992-03-09 Konica Corp 感熱転写記録材料
JPH08501100A (ja) * 1992-09-09 1996-02-06 イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー 除草性ベンゼン化合物
AU756586C (en) * 1997-07-01 2004-01-29 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
AU1529799A (en) 1997-12-23 1999-07-12 Warner-Lambert Company Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis
EP1339702A1 (en) * 2000-03-15 2003-09-03 Warner-Lambert Company 5-amide substituted diarylamines as mek inhibitors
FR2836917B1 (fr) * 2002-03-11 2006-02-24 Lipha Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant en tant que medicaments utilisables dans le traitement des pathologies caracterisees par une situation de stress oxydatif
US20050182040A1 (en) * 2002-04-03 2005-08-18 Naonori Imazaki Benzamide derivatives
WO2005009344A2 (en) 2003-06-05 2005-02-03 Elan Pharmaceuticals, Inc. Acylated amino acid amidyl pyrazoles and related compounds
US7504401B2 (en) 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
FR2862965B1 (fr) * 2003-11-27 2007-09-07 Merck Sante Sas Nouveaux derives de phenoxyacetamides et leur utilisation pour la preparation de diphenylamides.
WO2006127133A2 (en) * 2005-04-01 2006-11-30 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
TWI396543B (zh) * 2005-05-12 2013-05-21 Sankyo Co 取代丙烯醯胺衍生物及含有它之醫藥組成物
WO2006137376A1 (ja) * 2005-06-21 2006-12-28 Mitsui Chemicals, Inc. アミド誘導体ならびに該化合物を含有する殺虫剤
EP1754483A1 (en) 2005-08-18 2007-02-21 Merck Sante Use of thienopyridone derivatives as AMPK activators and pharmaceutical compositions containing them
EP1945208A4 (en) 2005-10-06 2011-08-03 Univ Massachusetts Composition and synthesis of new reagents for inhibition of hiv replication
GB0813403D0 (en) 2008-07-22 2008-08-27 Lectus Therapeutics Ltd Potassium ion channel modulators & uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03278050A (ja) * 1990-03-27 1991-12-09 Konica Corp ハロゲン化銀写真感光材料
WO2001068619A1 (en) * 2000-03-15 2001-09-20 Warner-Lambert Company 5-amide substituted diarylamines as mex inhibitors
WO2004035037A2 (en) * 2002-10-21 2004-04-29 Ramot At Tel Aviv University Ltd. Derivatives of n-phenylanthranilic acid and 2-benzimidazolon as potassium channel and/or cortical neuron activity modulators
CN101184726A (zh) * 2004-12-15 2008-05-21 冬姆佩制药股份公司 2-芳基丙酸衍生物及包含它们的药物组合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YANEEY D.WARD，ET AL: "Solid Phase Synthesis of Aryl Amines Via Palladium Catalyzed Amination of Resin-Bound Aromatic Bromides", 《TETRAHEDRON LETTERS》 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110913689A (zh) * 2017-05-10 2020-03-24 罗切斯特大学 治疗神经精神病症的方法
CN111433185A (zh) * 2017-10-09 2020-07-17 拉莫特特拉维夫大学有限公司 钾离子及trpv1通道的调节剂及其用途
US12084458B2 (en) 2021-02-19 2024-09-10 Sudo Biosciences Limited Substituted pyridines, pyridazines, and pyrimidines as TYK2 inhibitors
US12103937B2 (en) 2021-02-19 2024-10-01 Sudo Biosciences Limited Substituted pyridines and pyridazines as TYK2 inhibitors
US12122785B2 (en) 2021-02-19 2024-10-22 Sudo Biosciences Limited Substituted pyridines, pyridazines, pyrimidines, and 1,2,4-triazines as TYK2 inhibitors
CN117295711A (zh) * 2021-03-19 2023-12-26 艾可斯外扎根股份有限公司 Kv7通道开放剂的前药
CN117321031A (zh) * 2021-03-19 2023-12-29 艾可斯外扎根股份有限公司 Kv7通道开放剂的前药
CN117355503A (zh) * 2021-03-19 2024-01-05 艾可斯外扎根股份有限公司 Kv7通道开放剂的前药

Also Published As

Publication number Publication date
GB0813403D0 (en) 2008-08-27
JP2011529037A (ja) 2011-12-01
WO2010010380A1 (en) 2010-01-28
US20160374969A1 (en) 2016-12-29
EP2310357B1 (en) 2019-09-11
US9464052B2 (en) 2016-10-11
DK2310357T3 (da) 2019-11-25
US9675567B2 (en) 2017-06-13
US20110245250A1 (en) 2011-10-06
EP2310357A1 (en) 2011-04-20

Similar Documents

Publication Publication Date Title
CN102159535A (zh) 钾离子通道调节剂及其用途
CN102869656B (zh) 四氢苯并噻吩化合物
US8466201B2 (en) Potassium ion channel modulators and uses thereof
ES2654393T3 (es) Sulfonamidas como moduladores de los canales de sodio
JP2010504954A (ja) イオンチャネルモジュレータおよびその使用
WO2008149163A2 (en) Potassium ion channel modulators and uses thereof
CA2675884C (en) Quinoxaline compounds and use thereof
AU2011219885C1 (en) Compounds as bradykinin B1 antagonists
TW201010690A (en) Organic compounds
CA2836316A1 (en) Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
AU2008226666A1 (en) Spiro substituted compounds as angiogenesis inhibitors
EA012387B1 (ru) Производные бензодиазепина, содержащие их продукт и фармацевтическая композиция и их применение
CN110041327A (zh) 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用
HUE032169T2 (en) Quinoline and quinoxaline amides as modulators of sodium channels
WO1998027053A1 (en) Sulfonamide and carboxamide derivatives and drugs containing the same as the active ingredient
JP5778297B2 (ja) 癌治療用のｈｄａｃ阻害剤としての新規４−アミノ−ｎ−ヒドロキシ−ベンズアミド
AU2011290727B2 (en) Disubstituted tetrahydofuranyl compounds as antagonists of the bradykinin B1 receptor
RU2453540C2 (ru) 2,3-замещенные пиразинсульфонамиды в качестве ингибиторов crth2
WO2009019508A1 (en) Calcium ion channel modulators & uses thereof
BRPI0611537A2 (pt) (3,4-diidro-quinazolin-2-il) -(2-arilóxi-etil)-aminas tendo uma atividade sobre o receptor de 5-ht
CN104945324B (zh) 一种具有抗肿瘤活性的硫基类化合物及其应用
EP2299996A1 (en) 5-lipoxygenase inhibitors
KR20060008951A (ko) Ｉｐ 길항제로서 이미다졸린-2-일아미노페닐 아마이드
BRPI0713101A2 (pt) formas cristalinas de 6-metoxi-8-[4-(1(5-fluoro)-quinolin-8-il-piperidin-4-il)-pi perazin-1-il]-quinolina
CN108484635B (zh) 4H-噻吩并[2,3-b]噻喃-4-酮类化合物及其应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110817